Ladenburg Thalmann Financial Services’s BioCryst Pharmaceuticals BCRX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$88K	Sell	25,673 -500	-2%	-$1.26K	﹤0.01%	3119
2019 Q3	$75K	Buy	26,173 +25,550	+4,101%	+$79.5K	﹤0.01%	3142
2019 Q2	$3K	Buy	623 +134	+27%	+$806	﹤0.01%	4850
2019 Q1	$4K	Buy	489 +100	+26%	+$856	﹤0.01%	4720
2018 Q4	$3K	Sell	389 -100	-20%	-$778	﹤0.01%	4738
2018 Q3	$4K	Buy	489 +100	+26%	+$672	﹤0.01%	4658
2018 Q2	$2K	Hold	389	–	–	﹤0.01%	4838
2018 Q1	$2K	Hold	389	–	–	﹤0.01%	4838
2017 Q4	$2K	Hold	389	–	–	﹤0.01%	4750
2017 Q3	$2K	Hold	389	–	–	﹤0.01%	4644
2017 Q2	$2K	Hold	389	–	–	﹤0.01%	4569
2017 Q1	$3K	Hold	389	–	–	﹤0.01%	4452
2016 Q4	$2K	Hold	389	–	–	﹤0.01%	4509
2016 Q3	$2K	Sell	389 -20,000	-98%	-$79.9K	﹤0.01%	4448
2016 Q2	$58K	Buy	20,389 +10,000	+96%	+$31.1K	﹤0.01%	2563
2016 Q1	$29K	Buy	10,389 +10,000	+2,571%	+$44.3K	﹤0.01%	2983
2015 Q4	$4K	Hold	389	–	–	﹤0.01%	4109
2015 Q3	$4K	Sell	389 -7,000	-95%	-$93.4K	﹤0.01%	4013
2015 Q2	$110K	Buy	7,389 +3,500	+90%	+$39.8K	﹤0.01%	2032
2015 Q1	$35K	Buy	3,889 +389	+11%	+$4.03K	﹤0.01%	2814
2014 Q4	$43K	Buy	3,500 +500	+17%	+$5.52K	﹤0.01%	2459
2014 Q3	$29K	Hold	3,000	–	–	﹤0.01%	2367
2014 Q2	$38K	Buy	+3,000	New	+$29.2K	﹤0.01%	2212
2014 Q1	–	Sell	-1,000	Closed	-$8K	–	3752
2013 Q4	$8K	Hold	1,000	–	–	﹤0.01%	3038
2013 Q3	$7K	Sell	1,000 -27,000	-96%	-$137K	﹤0.01%	3017
2013 Q2	$43K	Buy	+28,000	New	+$48.3K	﹤0.01%	1823

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ladenburg Thalmann Financial Services's BCRX Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services reduced its BioCryst Pharmaceuticals (BCRX) stake by 1.9% in Q4 2019, selling an estimated $1.26K and leaving 25,673 shares worth $88K. The position accounts for ﹤0.01% of the portfolio, ranked #3119.

Ladenburg Thalmann Financial Services first reported a position in BCRX in Q2 2013 and has held it in 26 quarters since. The position peaked at $110K in Q2 2015. 136 funds tracked by Wall St. Rank hold BCRX as of Q4 2019.

Ladenburg Thalmann Financial Services held 25,673 shares of BioCryst Pharmaceuticals worth $88K as of Q4 2019.
Ladenburg Thalmann Financial Services sold 500 BioCryst Pharmaceuticals shares in Q4 2019, an estimated $1.26K.
BioCryst Pharmaceuticals made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #3119 holding.
Ladenburg Thalmann Financial Services first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 26 quarters since.
Ladenburg Thalmann Financial Services's BioCryst Pharmaceuticals position peaked at $110K in Q2 2015.
136 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.